- ASSOCIATE PROFESSOR Genetics and Genomic Sciences
- ASSOCIATE PROFESSOR Pediatrics
Clinical Biochemical Genetics
American Board of Pediatrics
- Biotinidase Deficiency
- Carnitine Disorders
- Disorders Of Cobalamin Metabolism
- Disorders Of Tetrahydrobiopterin Metabolism
- Fatty Acid Oxidation Defects
- Glutaric Acidemia
- Glycogen Storage Diseases
- Krabbe Disease
- Maple Syrup Urine Disease
- Metabolic Encephalopathy
- Methylmalonic Acidemia
- Mitochondrial Myopathy
- Newborn Screening
- Niemann-Pick Disease
- Organic Acidemias
- Pompe Disease
- Propionic Acidemia
- Urea Cycle Defects
MD, New York University
B.S, Cornell University
Mount Sinai Hospital
Fellowship, Human Genetics
Mount Sinai Hospital
- Clinical Interests: Medical Genetics, Pediatric Genetics, Inborn Errors of Metabolism, Lysosomal Storage Diseases, Newborn Screening, Urea Cycle Disorders, Hyperammonemia, Fatty Acid Oxidation Defects, Organic Acidemias, Maple Syrup Urine Disease
Dr. Wasserstein is the Director of the Program for Inherited Metabolic Diseases (PIMD) at Mount Sinai Medical Center. This program is one of the largest metabolic disease treatment programs in the country, treating several hundred patients who are diagnosed with rare inborn errors of metabolism. The PIMD is a New York State Newborn Screening designated referral center for infants with inherited metabolic diseases, and is also the leading referral center in the region for the evaluation of patients with suspected inborn errors of metabolism. Disorders that are treated at the PIMD include:
* Phenylketonuria (PKU)
* Maple Syrup Urine Disease
* Urea Cycle Defects
* Organic Acidemias
* Fatty Acid Oxidation Defects
* Glycogen Storage Diseases
* Mitochondrial Diseases
* Disorders of cobalamin metabolism
* Biotinidase deficiency
Dr. Wasserstein is part of Mount Sinai's International Center for Types A and B Niemann-Pick disease. She is also a clinical researcher, focusing on evaluating the safety and effectiveness of novel treatments for patients with inborn errors of metabolism.
In the News:
Dr. Wasserstein discusses testing babies for metabolic disorders in the The Daily News feature, The Daily Check Up.
Clinical trials to evaluate the safety and effectiveness of new treatments for patients with
- Types A and B Niemann-Pick disease
McGovern MM, Wasserstein MP, Giugliani R, Bembi B, Vanier MT, Mengel E, Brodie SE, Mendelson D, Skloot G, Desnick RJ, Kuriyama N, Cox GF. A prospective, cross-sectional survey study of the natural history of Niemann-Pick disease type B. Pediatrics 2008 Aug; 122(2): e341-349.
Wasserstein M, McGovern MM. Genetic basis of the lipid storage disorders. Future Lipidology 2008 April; 3(2): 189-201.
Willis A, Vanhuse C, Newton K, Wasserstein M, Morotti R. Farber Disease Type IV Presenting with Cholestatic Jaundice and neonatal liver failure:Report of Two Cases. Pediatr Dev Pathol 2007 Sept; 28(1).
Mc Guire PJ, Lim-Melia E, Diaz GA, Raymond K, Larkin A, Wasserstein MP, Sansaricq C. Combined liver-kidney transplant for the management of methylmalonic aciduria: A case report and review of the literature. Mol Genet Metab 2007 Oct 25;.
Salomons GS, Gibson KM, Landegge Pope L, Errami A, Potter M, Nowaczyk M, Olpin S, Manning N, Raiman JJ, Slade T, Champion MP, Peck D, Gavrilov D, Hillman R, Hoganson GE, Donaldson K, Shield JH, Ketteridge D, Wasserstein MP, Jakobs C. Clinical, enzymatic and molecular characterization of nine new patients with malonyl-coenzyme A decarboxylase deficiency. J Inherit Metab Dis 2007 Feb; 30(1): 23-28.
Wasserstein MP, Aron A, McGovern MM, Simonaro C, Desnick RJ, Brodie SE. Acid sphingomyelinase deficiency: Prevalence and characterization of an intermediate phenotype of Niemann-Pick disease. J Pediat 2006 October; 149(4): 554-559.
McGovern MM, Aron A, Wasserstein MP, Desnick RJ, Brodie SE. Natural history of Type A Niemann-Pick disease: possible endpoints for therapeutic trials. Neurology 2006 Jan 24; 66(2): 228-232.
Wasserstein MP, Buchsbaum MS, Sansaricq C, Snyderman SE. Cerebral glucose metabolism in patients with early treated classical phenylketonuria. Molec Genet Metab 2006 March; 87: 272-277.
Mendelson DS, Wasserstein MP, Desnick RJ, Glass R, McGovern MM, Skloot G, Vanier M, Bembi B, Giugliani R, Simpson W. Findings and Pulmonary Function in Niemann-Pick Disease Type B. Radiology 2006 Jan; 238(1): 339-345.
Wasserstein MP, Desnick RJ, Schuchman EH, McGovern MM, Wallenstein S, Lamm C, Hossain S. Natural history of type B Niemann-Pick Disease: results from a ten. Pediatrics 2004 Dec; 114(6): 672-677.
- An Open-Label, Multicenter, Ascending Dose Study Of The Tolerability And Safety Of Recombinant Human Acid Sphingomyelinase (rhASM) In Patients With Acid Sphingomyelinase Deficiency (ASMD)
- Niemann-Pick Disease:Genotype/Phenotype Analysis
- Long-term Extension of a Phase 2, Open-Label Dose-Finding Study to Evaluate the Safety, Efficacy, and Tolerability of Multiple Subcutaneous Doses of rAvPAL-PEG in Subjects with PKU (BioMarin Pharmaceutical Inc. Protocol PAL-003)
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Wasserstein during 2014 and/or 2015. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
- BioMarin Pharmaceutical Inc.; Genzyme Corporation
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians who provide services at hospitals and facilities in the Mount Sinai Health System might not participate in the same health plans as those Mount Sinai hospitals and facilities (even if the physicians are employed or contracted by those hospitals or facilities).
Information regarding insurance participation and billing by this physician may be found on this page, and can also be obtained by contacting this provider directly. Because physicians insurance participation can change, the insurance information on this page may not always be up-to-date. Please contact this physician directly to obtain the most up-to-date insurance information.
Insurance and health plan networks that the various Mount Sinai Health System hospitals and facilities participate in can be found on the Mount Sinai Health System website.
Atran Berg Laboratory Building Floor 1 Room AB1-45
1428 Madison Avenue
New York, NY 10029
1428 Madison Avenue
1st Floor, Room AB1-12
New York, NY 10029
- Monday 8:00am - 5:00pm
- Tuesday 8:00am - 5:00pm
- Wednesday 9:00am - 1:00pm
- Thursday 9:00am - 1:00pm
- Friday 8:00am - 5:00pm
- CIGNA - Indemnity
- Healthnet-Empire BCBS
- Oxford Health Plans
- United Health Care Empire Plan
- Workers' Compensation